Wave Life Sciences Ltd.
WVE
Rank in Stocks
#10493
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs,... Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company’s medicines platform, PRISM combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; WVE-007, a GalNAc-conjugated small interfering RNA designed to silence INHBE mRNA targeting obesity; WVE-008, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of liver disease; WVE-N531, an exon splicing oligonucleotide for the treatment of Duchenne muscular dystrophy; and WVE-003, an allele-selective oligonucleotide for the treatment of Huntington’s disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was founded in 2012 and is based in Singapore.
Share Price
$3.48
Last synced: 2026-11-09
Market Cap
$686.36M
Change (1 day)
3.42%
Change (1 year)
-52.07%
Country
Stock data: Financial Modeling Prep·Updated ·Not investment advice·How we calculate this
Trade Wave Life Sciences Ltd. (WVE)
Category
Healthcare
Operating Margin for Wave Life Sciences Ltd. (WVE)
Operating Margin as of November 2026 TTM: -320.94%
According to Wave Life Sciences Ltd.'s latest financial reports, its current operating margin (TTM) is -320.94%. At the end of 2025 the company had an operating margin of -504.09%.
Operating Margin history for Wave Life Sciences Ltd. from 2013 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -320.94% | -36.33% |
| 2025 | -504.09% | 394.50% |
| 2024 | -101.94% | 69.87% |
| 2023 | -60.01% | -98.65% |
| 2022 | -4,459.30% | 1,338.16% |
| 2021 | -310.07% | -59.41% |
| 2020 | -763.94% | -41.39% |
| 2019 | -1,303.37% | 17.77% |
| 2018 | -1,106.72% | -60.04% |
| 2017 | -2,769.44% | -25.67% |
| 2016 | -3,725.72% | -70.65% |
| 2015 | -12,696.05% | 0.00% |
| 2014 | 0.00% | 0.00% |
| 2013 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.12% |
US
|
|
| -149.01% | -99.54% |
US
|
|
| 25.57% | -100.08% |
AU
|
|
| 31.23% | -100.10% |
BE
|
|
| 29.35% | -100.09% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Wave Life Sciences Ltd.'s operating margin
What is Wave Life Sciences Ltd.'s operating margin?
Wave Life Sciences Ltd.'s operating margin is -320.94%, as of Nov 2026.
What was Wave Life Sciences Ltd.'s operating margin in 2025?
In 2025, Wave Life Sciences Ltd.'s operating margin was -504.09%, compared with -101.94% in 2024.
How has Wave Life Sciences Ltd.'s operating margin changed since 2020?
From 2020 to 2025, Wave Life Sciences Ltd.'s operating margin was highest in 2023 (-60.01%) and lowest in 2022 (-4,459.30%).
How does Wave Life Sciences Ltd.'s operating margin compare with similar companies?
Wave Life Sciences Ltd.'s operating margin (-320.94%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.